Drug Profile
Research programme: alcoholism therapeutics - ADial Pharmaceuticals
Alternative Names: Naltrexone/ondansetron/topiramate; Naltrexone/topiramate; Naltrexone/topiramate/ondansetron; Ondansetron/naltrexone/topiramate; Ondansetron/topiramate/naltrexone; Topiramate/naltrexone; Topiramate/naltrexone/ondansetron; Topiramate/ondansetron/naltrexoneLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ADial Pharmaceuticals
- Class Carbazoles; Hexoses; Imidazoles; Ketoses; Morphinans; Small molecules; Sulfonic acids
- Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Opioid receptor antagonists; Serotonin 3 receptor antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alcoholism
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alcoholism in USA
- 01 Apr 2013 Preclinical trials in Alcoholism in USA (unspecified route)